Fibroblast Growth Factor 23 Concentrations in Humoral Hypercalcemia of Malignancy and Hyperparathyroidism

Singh, Ravinder J.; Kumar, Rajiv
July 2003
Mayo Clinic Proceedings;Jul2003, Vol. 78 Issue 7, p826
Academic Journal
• Objective: To determine whether fibroblast growth factor 23 (FGF 23) concentrations are increased in the serum of patients with humoral hypercalcemia of malignancy and in those with hyperparathyroidism. • Patients and Methods: Serum samples from patients with hypercalcemia and documented elevations of parathyroid hormone-related protein or parathyroid hormone levels were examined for FGF 23 concentrations. Specimens from healthy age-matched controls were evaluated to establish a reference range for FGF 23. • Results: Mean ± SEM concentrations of FGF 23 were elevated in the 7 patients with humoral hypercalcemia of malignancy (385 ± 134 relative unit [RU]/mL) compared with 11 healthy controls (43.9 ± 5.8 RU/mL; P=.005). In the 11 patients with hyperparathyroidism, FGF 23 concentrations were increased (mean ± SEM 86.6 ± 22.8 RU/mL), but the increases were not statistically significant. The increases in FGF 23 in these disorders did not correlate with changes in serum phosphate or 1α,25-dihydroxyvitamin D levels. • Conclusion: Levels of FGF 23 are elevated in patients with tumors associated with humoral hypercalcemia of malignancy. The precise cause of such elevations requires further investigation.


Related Articles

  • Parathyroid diseases and animal models. Imanishi, Yasuo; Nagata, Yuki; Inaba, Masaaki // Frontiers in Endocrinology;May2012, preceding p1 

    Circulating calcium and phosphate are tightly regulated by 3 hormones: the active form of vitamin D (1,25-dihydroxyvitamin D), fibroblast growth factor (FGF)-23, and parathyroid hormone (PTH). PTH acts to stimulate a rapid increment in serum calcium and has a crucial role in calcium homeostasis....

  • Calcium Metabolism & Hypercalcemia in Adults. Lumachi, F.; Motta, R.; Cecchin, D.; Ave, S.; Camozzi, V.; Basso, S. M. M.; Luisetto, G. // Current Medicinal Chemistry;Aug2011, Vol. 18 Issue 23, p3529 

    Calcium is essential for many metabolic process, including nerve function, muscle contraction, and blood clotting. The metabolic pathways that contribute to maintain serum calcium levels are bone remodeling processes, intestinal absorption and secretion, and renal handling, but hypercalcemia...

  • FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Ketteler, Markus; Biggar, Patrick H.; Liangos, Orfeas // Nephrology Dialysis Transplantation;Apr2013, Vol. 28 Issue 4, p821 

    For more than 10 years, we have been convinced by overwhelming epidemiological evidence with a high biological plausibility that hyperphosphataemia imposes one of the most sustained cardiovascular and mortality risks on patients suffering from chronic kidney disease (CKD). With the discovery of...

  • Hungry bone syndrome and normalisation of renal phosphorus threshold after total parathyroidectomy for tertiary hyperparathyroidism in X-linked hypophosphataemia: a case report. Crowley, Rachel K.; Kilbane, Mark; King, Thomas F. J.; Morrin, Michelle; O'Keane, Myra; McKenna, Malachi J. // Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p1 

    Introduction This is the first report of which the authors are aware to describe this c.2166delinsGG mutation in X-linked hypophosphataemia and to describe normalisation of renal threshold for phosphate excretion after parathyroidectomy for tertiary hyperparathyroidism in X-linked...

  • The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease. Cozzolino, Mario; Mazzaferro, Sandro // Current Vascular Pharmacology;May2010, Vol. 8 Issue 3, p404 

    Recently, a new view into the molecular mechanisms of phosphate homeostasis and secondary hyperparathyroidism pathogenesis has been proposed, with Fibroblast Growth Factor 23 (FGF-23) as a novel player in the field. Enhanced serum FGF-23 levels cause a reduction in serum phosphate, together with...

  • Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Hansen, Ditte; Rasmussen, Knud; Pedersen, Susanne M.; Rasmussen, Lars M.; Brandi, Lisbet // Nephrology Dialysis Transplantation;Jun2012, Vol. 27 Issue 6, p2263 

    Background. Fibroblast growth factor 23 (FGF23) increases renal phosphate excretion and decreases the formation of 1,25 dihydroxyvitamin D. In patients with chronic kidney disease, plasma FGF23 levels are markedly elevated by unknown mechanisms. We explored the changes in FGF23 during treatment...

  • FGF23–parathyroid interaction: implications in chronic kidney disease. Komaba, Hirotaka; Fukagawa, Masafumi // Kidney International;Feb2010, Vol. 77 Issue 4, p292 

    Over the past few years there have been considerable advances in our understanding of the physiological regulation of mineral homeostasis. One of the most important breakthroughs is the identification of fibroblastic growth factor 23 (FGF23) and its role as a key regulator of phosphate and...

  • Cortisone Responsive Hypercalcemia in Proved Hyperparathyroidism. Gwinup, Grant; Sayle, Bettye // Annals of Internal Medicine;Dec61, Vol. 55 Issue 6, p1001 

    Reports cases of cortisone responsive hypercalcemia in proved hyperparathyroidism. Differential diagnosis; Hypercalcemia of sarcoidosis; Relationship between hypercalcemia and neoplasm.

  • Humoral Hypercalcemia of Malignancy. Burtis, William J.; Wu, Terence L.; Insogna, Karl L.; Stewart, Andrew F. // Annals of Internal Medicine;Mar88, Vol. 108 Issue 3, p454 

    Editorial. Focuses on humoral hypercalcemia of malignancy. Nature of hypercalcemia; Syndromes of humoral hypercalcemia of malignancy; Difference between patients with humoral hypercalcemia of malignancy and patients with primary hyperparathyroidism.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics